In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 371 to 380 of 447

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]	Technology appraisal guidance	TBC
Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]	Technology appraisal guidance	TBC
Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]	Technology appraisal guidance	11 March 2026
Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]	Technology appraisal guidance	TBC
Sotatercept for treating pulmonary arterial hypertension [ID6163]	Technology appraisal guidance	TBC
Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over TSID 12091	Technology appraisal guidance	TBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632	Technology appraisal guidance	TBC
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]	Technology appraisal guidance	TBC
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)	Medical technologies guidance	TBC
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]	Technology appraisal guidance	21 April 2021

Results per page